GlassScriptPhysician profile
Andrew A Muskovitz
NPI 1558544510
$44,580.66
in general payments reported to CMS, 2019-2025
54 companies · $371 in 2025
The $371 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30K · 2020: $6,785 · 2021: $1,493 · 2022: $2,242 · 2023: $3,236 · 2024: $104 · 2025: $371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,877 · Consulting Fee: $338 · Long Term Medical Supply Or Device Loan: $283 · Education: $213.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,876.73 |
| Consulting Fee | $337.50 |
| Long Term Medical Supply Or Device Loan | $282.73 |
| Education | $213.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Puma Biotechnology, INC. | $31,428.23 | 2019-2020 | |
| Abbvie INC. | $3,703.57 | 2020-2025 | |
| Genentech USA, INC. | $3,135.80 | 2020-2023 | Lunsumio, Polivy, Tecentriq |
| Daiichi Sankyo INC. | $974.33 | 2020-2023 | Enhertu |
| Novartis Pharmaceuticals Corporation | $903.90 | 2021-2023 | |
| Amgen INC. | $759.22 | 2019-2023 | Kyprolis, Nplate, Blincyto |
| Genzyme Corporation | $256.56 | 2022-2023 | |
| Janssen Biotech, INC. | $198.38 | 2019-2023 | Darzalex, Tecvayli, Imbruvica |
| Genmab U.S., INC. | $186.36 | 2023-2025 | Epkinly |
| Astellas Pharma US INC | $160.55 | 2023 | Padcev, Xospata |
| Pfizer INC. | $156.85 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $143.75 | 2019-2023 | Iclusig, Cuvitru, Ninlaro |
| Glaxosmithkline, LLC. | $128.84 | 2020-2025 | Ojjaara, Shingrix, Blenrep |
| E.R. Squibb & Sons, L.L.C. | $128.75 | 2020-2025 | Opdivo |
| Astrazeneca Pharmaceuticals LP | $127.81 | 2020-2023 | Enhertu, Tagrisso, Calquence |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $127.00 | 2022-2024 | |
| Emd Serono, INC. | $126.43 | 2022-2023 | Tepmetko, Bavencio |
| Sanofi-Aventis U.S. LLC | $113.86 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $109.62 | 2022-2023 | |
| Seagen INC. | $108.00 | 2020-2023 | Padcev |
| Beigene USA, INC. | $107.78 | 2022-2023 | Brukinsa |
| Merck Sharp & Dohme LLC | $90.78 | 2022-2023 | Keytruda, Lynparza |
| Exelixis INC. | $89.35 | 2022-2023 | Cabometyx |
| Eisai INC. | $85.55 | 2022-2023 | |
| Mirati Therapeutics, INC. | $83.89 | 2023 | Krazati |
| Gilead Sciences, INC. | $81.40 | 2021-2023 | Trodelvy |
| Sumitomo Pharma America, INC. | $78.96 | 2023 | Orgovyx |
| Incyte Corporation | $77.57 | 2022 | |
| Lilly USA, LLC | $75.37 | 2021-2023 | Verzenio |
| Sobi, INC | $63.29 | 2023 | |
| Kite Pharma, INC. | $60.89 | 2021-2023 | Yescarta |
| Servier Pharmaceuticals LLC | $59.75 | 2022-2023 | |
| G1 Therapeutics, INC. | $57.17 | 2022 | |
| Array Biopharma INC | $51.64 | 2023-2025 | Braftovi, Mektovi, Lorbrena |
| Ipsen Biopharmaceuticals, INC | $51.02 | 2022-2023 | Onivyde, Somatuline Depot |
| Pharmacosmos Therapeutics INC. | $47.99 | 2023-2025 | Monoferric |
| Pharmacyclics LLC, An Abbvie Company | $41.67 | 2023 | Imbruvica, Epkinly |
| Celgene Corporation | $38.85 | 2021-2023 | Reblozyl |
| Caris Mpi, INC. | $38.73 | 2025 | Mi Cancer Seek |
| Alnylam Pharmaceuticals INC. | $37.93 | 2020-2023 | Givlaari |
| Tersera Therapeutics LLC | $31.87 | 2022-2023 | Zoladex |
| Regeneron Healthcare Solutions, INC. | $25.48 | 2025 | Lynozyfic |
| Taiho Oncology, INC. | $24.73 | 2023 | |
| Pharmaessentia USA Corporation | $24.56 | 2023 | Besremi |
| Blueprint Medicines Corporation | $23.04 | 2023 | Ayvakit |
| Apellis Pharmaceuticals, INC. | $20.46 | 2023 | Empaveli |
| Recordati_rare_diseases_inc. | $18.47 | 2022 | |
| Eusa Pharma (US) LLC | $18.46 | 2022 | |
| Deciphera Pharmaceuticals INC. | $17.12 | 2023 | Qinlock |
| Stemline Therapeutics INC. | $16.87 | 2023 | Orserdu |
| Amag Pharmaceuticals, INC. | $16.50 | 2022 | |
| Karyopharm Therapeutics INC. | $15.84 | 2023 | Xpovio |
| Morphosys, US INC. | $15.17 | 2023 | Monjuvi |
| Octapharma USA, INC. | $14.70 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Muskovitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.